1. Home
  2. SOS vs QNRX Comparison

SOS vs QNRX Comparison

Compare SOS & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

HOLD

Current Price

$0.99

Market Cap

9.9M

Sector

Finance

ML Signal

HOLD

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

N/A

Current Price

$4.20

Market Cap

11.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOS
QNRX
Founded
2004
2018
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
11.6M
IPO Year
2005
2023

Fundamental Metrics

Financial Performance
Metric
SOS
QNRX
Price
$0.99
$4.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.2K
31.1K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$4.11
52 Week High
$8.92
$41.80

Technical Indicators

Market Signals
Indicator
SOS
QNRX
Relative Strength Index (RSI) 38.34 33.91
Support Level $0.90 N/A
Resistance Level $1.56 $6.84
Average True Range (ATR) 0.05 0.49
MACD -0.01 0.03
Stochastic Oscillator 35.75 8.17

Price Performance

Historical Comparison
SOS
QNRX

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: